Cetera Trust Company N.A Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cetera Trust Company N.A lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,923 shares of the company’s stock after acquiring an additional 229 shares during the quarter. Cetera Trust Company N.A’s holdings in Johnson & Johnson were worth $278,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Dark Forest Capital Management LP bought a new position in shares of Johnson & Johnson during the 2nd quarter worth $223,000. Peloton Wealth Strategists raised its position in shares of Johnson & Johnson by 3.1% in the second quarter. Peloton Wealth Strategists now owns 16,749 shares of the company’s stock worth $2,448,000 after buying an additional 496 shares in the last quarter. Texas Capital Bancshares Inc TX grew its holdings in shares of Johnson & Johnson by 26.3% during the second quarter. Texas Capital Bancshares Inc TX now owns 5,268 shares of the company’s stock worth $770,000 after purchasing an additional 1,096 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc grew its stake in Johnson & Johnson by 25.6% in the 2nd quarter. Texas Capital Bank Wealth Management Services Inc now owns 4,997 shares of the company’s stock worth $730,000 after buying an additional 1,019 shares in the last quarter. Finally, Bontempo Ohly Capital Mgmt LLC raised its position in Johnson & Johnson by 0.8% during the second quarter. Bontempo Ohly Capital Mgmt LLC now owns 14,650 shares of the company’s stock valued at $2,141,000 after purchasing an additional 115 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on JNJ. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday. Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Leerink Partners dropped their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Raymond James reduced their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $170.06.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $146.76 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $353.34 billion, a PE ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. The stock has a 50-day simple moving average of $147.85 and a two-hundred day simple moving average of $155.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same period last year, the firm earned $2.29 earnings per share. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.